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ABSTRACT 
 
S100 Inhibitors: A New Paradigm for Treating Alzheimer’s Disease. (April 2011) 
 
David Mathai 
Department of Biochemistry 
Texas A&M University 
 
Research Advisor: Dr. Danna Zimmer 
Department of Veterinary Pathobiology 
 
Alzheimer’s disease (AD) is the most common form of dementia, a neurological 
condition characterized by cognitive impairment and the inability to perform daily tasks. 
Neuritic protein aggregates in the brain, known as plaques, are a hallmark of AD 
pathology. These plaques are deposits of the amyloid- (A) peptide, which is derived 
from a larger molecule known as the amyloid precursor protein (APP). APP can be 
processed in one of two ways: in the non-amyloidogenic pathway, APP cleavage 
generates a variety of fragments that are thought to promote neuronal growth and 
survival; in the amyloidogenic pathway, APP cleavage leads to the production of the 
neurotoxic A peptide. Our lab has recently demonstrated that inhibition of two 
members of the S100 family of calcium binding proteins, S100A1 and S100B, 
synergistically reverses cognitive decline in the PSAPP mouse model of AD. However, 
the molecular underpinnings of this process are not known. This study tests the 
hypothesis that improved cognition, which is accompanied by a reduction in plaque load, 
is due to increased non-amyloidogenic APP processing. Western blotting was used to 
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quantify the levels of full-length APP and A in brain lysates from 12-14 month old 
PSAPP and PSAPP/S100 knockout mice. APP and Aβ levels were similar in 
PSAPP/S100 knockout and PSAPP mice. These data suggest that the decreased 
pathology observed in PSAPP/S100 knockout mice is not attributable to alternative 
processing of APP. Future directions of study include an examination of other possible 
mechanisms that may be responsible for observed differences in pathology. The 
molecular processes of plaque buildup and Aβ clearance have been proposed as targets 
for further study in S100 knockout mice.   Once identified, this mechanistic information 
can be used toward the development of S100 inhibitors that improve memory loss in 
patients. The availability of novel pharmacological interventions for AD will 
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APP  Amyloid precursor protein 
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Due to the increasing life-expectancy of the American population and the decline of 
heart disease, cancer, and stroke, Alzheimer’s disease (AD) will soon be the leading 
cause of death in America (Alzheimer’s Association, 2011). AD is the most common 
form of dementia, a neurological condition characterized by cognitive impairment and 
the inability to perform daily tasks. About 5.4 million Americans are estimated to have 
AD, 5.2 million of whom are age 65 or older (Alzheimer’s Association, 2011). In 
addition to the societal impact of the disease, AD puts a significant financial burden on 
the economy. In 2011 alone, America will spend $183 billion on AD-related health care, 
aside from the loss of productivity and related care-giving expenses incurred 
(Alzheimer’s Association, 2011). The indirect per-patient cost of Alzheimer’s taken on 
by primary caregivers is estimated to exceed $8,000 a year (Turró-Garriga et al., 2010). 
The extensive impact of this debilitating disease can largely be attributed to a lack of 
effective treatment; existing medications slow the worsening of symptoms in only some 
patients and, even then, only for a limited time. As such, the identification of novel 
therapeutics that target the underlying neuronal dysfunction in AD is a high priority. It is 
thus critical to further delineate the biochemical basis of the disease pathology. 
_______________ 
This thesis follows the style of The Journal of Neuroscience. 
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 The amyloid cascade hypothesis is the prevalent theory for the intricate AD 
pathophysiology that includes the development of neuritic protein aggregates known as 
plaques and twisted neurofibrillary fibers known as tangles (Simón et al., 2010). This 
hypothesis states that dysregulation of amyloid precursor protein (APP) processing 
ultimately leads to dementia in AD patients. There are two main forms of AD that 
progress similarly.  In early-onset AD, symptoms begin to appear in an individual’s 40s 
and 50s and are usually caused by genetic mutations within families that lead to the 
accumulation of amyloid-β (Aβ), a toxic protein fragment (Alzheimer’s Association, 
2010). However, these account for only a small percent of diagnoses. Over 95% of AD 
cases are classified as late-onset; these incidences affect individuals in their 60s and 
older and usually occur sporadically, without a direct genetic basis for inheritance (Tanzi 
and Bertram, 2005). The inheritance of sporadic AD is less certain and has been 
attributed to a combination of genetic, lifestyle, and environmental factors (Blennow et 
al., 2006). In these cases, failure of normal clearance mechanisms contributes to Aβ 
peptide accumulation (Revesz et al., 2002). Nevertheless, in both forms of AD, the 
increase in Aβ levels is recognized as the initiating event that induces neurodegeneration 
and synaptic loss that result in characteristic cognitive decline (Thinakaran and Koo, 
2008).   
 
The neurotoxic peptide, Aβ, is derived from APP, which can be processed in one of two 
ways (Fig. 1 A). In the non-amyloidogenic pathway, the proteolytic enzymes α-secretase 
and -secretase serially cleave APP, generating a variety of protein fragments. The initial 
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α -secretase cleavage generates a long secreted form of amino-terminal APP (sAPPα) 
and a C-terminal fragment known as APP-CTF83 (CTF83). Subsequent cleavage by -
secretase releases the APP intracellular domain (AICD50) and the P3 fragment. These 
nonamyloidogenic fragments are thought to promote neuronal growth, survival, and 
differentiation (Chow et al., 2010). In the amyloidogenic pathway, β-secretase (β-site 























Figure 1. The role of S100 proteins in APP processing. A, APP can be cleaved via an amyloidogenic or 
a nonamyloidogenic processing pathway, generating a variety of protein fragments. Amyloidogenic 
processing gives rise to toxic Aβ. B, Certain S100 proteins are suspected to act at a molecular level by 
increasing total APP levels and amyloidogenic processing (solid arrows) and by inhibiting 
nonamyloidogenic processing.  
 
  4 
CTF99. The presence of multiple APP cleavage sites leads to the production of a variety 
of peptide isoforms; for instance, CTF89 is often found along with CTF99 following β-
secretase action.  Further processing by -secretase results in the formation of AICD50 
and the Aβ peptides responsible for AD pathology. As before, the presence of multiple 
proteolytic sites results in a variety of fragment lengths: Aβ1-40 is the most common 
isoform, and the more toxic Aβ1-42 peptide is normally found in lower amounts. In AD 
pathology, mutations in APP or -secretase lead to the increased prevalence of Aβ1-42 
after processing (Tanzi and Bertram, 2005). Aβ1-42 aggregates readily and accumulates 
as both soluble oligomeric aggregates and insoluble amyloid plaques. The relative levels 
of CTF83 and CTF89/99 can also be used to quantify amyloidogenic and 
nonamyloidogenic APP processing. Agents that decrease amyloidogenic processing 
and/or increase nonamyloidogenic processing could be used in patients to slow disease 
progression.  
 
Recent findings suggest that several members of the S100 protein family may be 
implicated in APP processing (Mori et al., 2010). The S100 Ca
2+ 
binding family is 
comprised of over 21 members, and many of these proteins are known to play a role in 
various neurodegenerative disorders (Hoyaux et al., 2000). The AD brain is known to 
exhibit disrupted calcium homeostasis and elevated levels of several S100 proteins 
(Supnet and Bezprozvanny, 2010). S100 proteins are suspected to mediate APP 
processing at several points along its metabolic pathway (Fig. 1 B). Overexpression of 
one family member, S100B, increases pathogenesis and total Aβ levels in a transgenic 
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AD mouse model (Mori et al., 2010). In the same experiment, elevated CTF99 and 
sAPPβ products were detected, suggesting that the increase in Aβ was due to increased 
amyloidogenic processing; this conclusion was further supported by a concurrently 
observed increase in β-secretase expression and activity.  Conversely, AD progression is 
mitigated when S100B synthesis is blocked chemically (Mori et al., 2006). The 
interactions of S100B and its target, the receptor for advanced glycation endproducts 
(RAGE) have been suggested as critical areas for future AD study (Leclerc et al., 2010). 
In addition, studies show that ablation of S100A1 in neuronal cells reduces intracellular 
APP levels (Zimmer et al, 2005). Our lab has also recently demonstrated that ablation of 
both S100A1 and S100B synergistically reduces Aβ-load (unpublished observations). 
My proposal will test the central hypothesis that reduced Aβ-load in the S100A1/S100B 




) is due to decreased 
amyloidogenic processing and increased nonamyloidogenic processing of APP.  Western 
blotting will be used to achieve the following specific aims: 
(1) Quantify levels of full-length APP 
(2) Quantify levels of amyloidogenic A  
We expect that these studies will be the first to demonstrate whether or not inhibition of 
S100A1/S100B has a role in APP processing. If S100 proteins are implicated in 
processing, these results would suggest that S100 inhibitors could be used in patients to 
decrease levels of Aβ and improve cognitive function. Otherwise, several alternative 
mechanisms of regulation would be considered for therapeutic potential.  Nevertheless, 
the development of new, effective pharmacological interventions is critical for 
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combating the staggering impact that AD has on individuals living with the disease, 

























Experimental methods consisted of the development of mouse lines, brain lysates, 
western blotting, and quantification. A schematic of experimental design can be found in 
Figure 2.    
 
Mice 
The PSAPP line used was generated by crossing Tg2576 and 6.2 mouse lines. Tg2576 
mice express double missense mutations (K670N/M671L) that cause a dramatic increase 
in brain transgenic APP compared to endogenous APP and also result in increased levels 
of Aβ in the brain (Hsiao et al., 1996). The 6.2 line is characterized by a mutation 
(M146L) in Presenilin-1, a protein which is known to be involved in γ-secretase 
cleavage of APP (Duff et al., 1996).  The double transgenic PSAPP mouse model 
resulting from the cross consequently recapitulates AD-like processing and pathology 










mice and subsequent interbreeding of the heterozygous 
offspring. PSAPP littermates were used as controls to ensure that any measured 
differences were not attributable to differences in genetic background. All procedures 
were performed with approval from the Texas A&M University Institutional Animal 
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Care and Use committee in accordance with guidelines from the NIH Guide for the Care 




















Figure 2. Flow diagram of experimental design. 
 
How do brain S100 proteins 
affect APP levels and APP 
processing in a mouse model of 
Alzheimer’s disease? 
Compare 
PSAPP mice (control) PSAPP S100A1/S100B knockout 
mice (experimental) 
Take brain samples from ~ 1 year 
old transgenic mice 
Experiment 
Western blotting 
 Quantify APP and APP 
processing intermediates 
 Quantify soluble A 
What differences are seen? 
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Tissue preparation 
PSAPP (n = 5) and PSAPP ABKO (n = 5) mice aged twelve to fourteen months old were 
anesthetized, and brains removed, dissected, and frozen. Lysates were prepared by 
homogenizing 0.05g tissue with 1mL TPER containing 10 mM EDTA and 3X HALT 
inhibitor (Thermo Scientific, Rockford, IL). Soluble and insoluble fractions were 
prepared by centrifugation at 14000 rpm for 1 min at 4C. All samples were stored at -
80°C until use. Protein concentrations were determined by the Bradford method 
(Bradford, 1976).  
 
Western blot 
Western blot analysis was used to quantify the levels of full-length APP and APP 
processing intermediates. Samples of 10-20ug total protein in sample buffer (4% w/v 
SDS, 1 mM DTT, 0.075 glycerol, 1.2 mg/mL Bromophenol blue, 40 mM Tris-HCL, pH 
6.8) were then size-fractionated on 4-20% gradient SDS polyacrylamide gels (Bio-Rad, 
Hercules, CA). Precision Plus Protein Western C Standards (Bio-Rad) were used as 
molecular weight markers.  After gel electrophoresis, proteins were transferred to 
nitrocellulose membranes (Millipore, Billerica, MA) at 30 V for 60 min at 4C. 
Following transfer, membranes were blocked in non-fat dry milk [5% w/v non-fat dry 
milk, 0.1% v/v Tween 20, Tris-buffered saline (TBS) (200 mM NaCl, 50 mM tris, pH 
7.5)] for 60 min. After blocking, membranes were incubated with primary antibodies in 
non-fat dry milk: rabbit polyclonal C-terminal APP antibody (1:500 dilution of A8717; 
Sigma-Aldrich, St. Louis, MO), mouse monoclonal N-terminal APP antibody (clone 
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22c11; 1:10,000 dilution of MAB438; Millipore), mouse monoclonal C-terminal 
APP/Aβ isoform antibody (clone 6E10; 1:2,500 dilution of 39320; Covance, Princeton, 
NJ), and mouse monoclonal -actin antibody (clone AC15; 1:3,000 dilution of A1978; 
Sigma-Aldrich). After washing in TBS-T (1X TBS, 0.1 v/v % Tween 20), membranes 
were incubated in species specific HRP-labeled Goat anti-rabbit antibody (1:10,000 
dilution of A120-101P; Bethyl, Montgomery, TX) or HRP-labeled Goat anti-mouse IgG 
(1:10,000 dilution of 074- 1806, KPL) in non-fat dry milk and Precision Protein 
StrepTactin-HRP conjugate (Bio-Rad) to visualize molecular weight markers. After 
washing again in TBS-T, blots were developed using SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific). 
 
Quantification 
Antibody binding was visualized on ImageQuant LAS 4000 mini (GE Healthcare) and 
quantified using ImageQuant TL 7.0 Analysis Software (GE Healthcare).  The 
programmed rolling ball method was used to eliminate background and set a signal 
baseline. β-actin was used to normalize measured band pixel areas and account for 
variability and loading error. Following normalization, total APP and Aβ levels were 
expressed as mean ratios of pixel area + the standard error of the mean (SEM). An 
independent samples t-test was used to determine significance of measured differences 
(SPSS Inc., Chicago, IL).  
 
 




Western blot optimization 
To ensure the best possible signal to noise ratio in the Western blot immunoassay, it was 
necessary to test for optimal experimental conditions. To assess which transfer 
membrane provided maximum chemiluminescence signal with minimal background 
contribution, serial dilutions (1/1000 to 1/10000) of a total brain lysate were blotted onto 
polyvinylidene fluoride (PVDF) and nitrocellulose membranes and compared. To 
optimize chemiluminescence, the following development kits were used: Amersham, 
Amersham Basic, Amersham Advanced, SuperSignal Pico, and SuperSignal Femto. The 
optimal signal to noise ratios were obtained with the SuperSignal Femto kit and the 
nitrocellulose membrane. This combination was used to compare APP and A levels in 
PSAPP and PSAPP ABKO mice.          
 
To assess antibody specificity, the optimized dot blotting procedure was applied to 
samples of PSAPP and wild-type homogenate for primary antibody (22c11, 6E10, C-
terminal, and β-actin) and secondary antibody (HRP-labeled Goat anti-rabbit, HRP 
labeled Goat anti-mouse). Once the antibodies were found to bind and induce signal, 
conditions were again optimized for the Western blotting procedure that would be 
implemented. A comparison of sodium bicarbonate running buffer solution and a tris-
glycine based buffer showed that the tris-glycine buffer allowed for better separation of 
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bands during gel electrophoresis, when 10 ug of protein was loaded per gel lane.  The 
working dilution of β-actin, which would be used for normalization, was established to 
be 1-3000. Since 22c11 and C-terminal primary antibodies bound to their target proteins 
with limited success and a high degree of variance, 6E10 was chosen instead for APP/Aβ 
 
Table 1.Variability of APP and Aβ detection methods with 6E10. Relative levels of APP and Aβ in PSAPP 
and PSAPP ABKO mice ran on two different days. Mice were distinguished by a unique identification 
number, shown in Column 2. Multiple samples of each mouse lysate were run per day, normalized to β-
actin, and then averaged prior to further analysis.  
 
APP 
Quantification  I.D. Day 1 Day 2 
  PSAPP   
  1894 0.258183472 0.258183472 
  24 0.868717765 0.815585502 
  
PSAPP 
ABKO   
  1925 0.183923831 1.144750539 
Aβ Quantification     
  PSAPP   
  1894 0.068236378 0.071164 
  24 0.144885488 0.174851 
  
PSAPP 
ABKO   
  1925 0.048146112 0.068137 
 
 
quantification at a working concentration of 1-2500. Furthermore, since issues with C-
terminal antibody resolution prevented effective separation and measurement of the 
CTF89 and CTF99 APP fragments, and it was decided that the immunoassay would 
focus on a comparison of APP and Aβ levels, rather than amyloidogenic and 
nonamyloidogenic CTF fragments. To allow for ideal separation and visualization of  
 
























Figure 3. Quantification of APP and Aβ levels. A, Representative western blot image. Lanes 
correspond to lysates as follows, with mouse ID and genotype in parentheses: 1 (1894, PSAPP), 
2 (24, PSAPP), 3 (2001, PSAPP S100ABKO), 4 (1893, PSAPP), 5 (1976, PSAPP S100ABKO). 
Molecular weights of detected bands were determined by calibrating to standard markers, shown 
here indicating size in kilo Daltons (kDa).  B, The histograms depict cumulative data on APP 
and Aβ levels + SEM in PSAPP (gray bars, n = 5) and PSAPP S100 ABKO (orange bars, n = 5) 
mice. Values were expressed as relative amounts normalized to β-actin within gels and were 










  50 kDa 
  37 kDa 
  25 kDa 
  20 kDa 
  15 kDa 
  10 kDa 
1       2         3        4       5   
A 
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APP and Aβ bands, gels ran for 70 minutes (100 V) and were transferred for 1 hour (30 
V).  For 6E10 and B-actin primary antibodies, species specific HRP labeled Goat anti-
mouse secondary was used at concentrations of 1-10000 and 1-15000 respectively.  
 
APP/A quantification  
Membranes were cut horizontally along reference bands in the standard lane 
corresponding to molecular weights of 50 and 25 kDa  to allow for separate development 
of APP (~ 100 kDa), β-actin (~42 kDa), and Aβ (~6 kDa) bands. It was determined that 
additional bands present at 110, 50, 25 kDa were due to IgG binding and did not 
influence quantification of the other bands. Samples from PSAPP (n = 5) and PSAPP 
ABKO (n = 5) mice were quantified to determine amounts of APP and Aβ present in 
brain cortex tissue. APP and Aβ levels were expressed as relative ratios of respective 
protein area to β-actin area, to account for loading error (Tab. 1). The coefficient of 
variation between gels for PSAPP sample 1894 was used as a normalization factor. 
Average levels of APP and Aβ normalized to β-actin have been displayed along with 
standard error of the mean (Fig. 3). The two-tailed P value for mean differences in 
PSAPP and PSAPP ABKO mice was 0.7979 for the APP comparison and provided a P 
value of 0.7042 for the Aβ comparison, well above the 0.05 threshold set to assess 
significance. Thus, there is no difference in levels of APP and A in PSAPP and PSAPP 
ABKO mice.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
In summary, the Western blotting results demonstrated that respective APP and Aβ 




mice were indistinguishable. Although 
Tg2576 mice overexpressing S100B demonstrate increased levels of Aβ and 
amyloidogenic processing (Mori et al., 2010), PSAPP ABKO mice do not demonstrate 
the converse effect. This may be attributed to compensatory mechanisms that act to 
share the role of the absent S100 proteins. Since S100s have highly homologous protein 
structures, it is possible that the function of other similar proteins account for the 
similarities in APP and A levels in control and experimental mice.  
 
Future areas of study include the mechanisms of plaque buildup and Aβ clearance. 
S100A1 and S100B may work to regulate the relative production of Aβ isoforms. This 
effect may resemble the activity of certain mutations in familial AD that cause the more 
aggregate-prone Aβ1-42 variant to predominate over Aβ1-40 and thereby contributing to 
differences in plaque load. The current experimental conditions were directed toward 
quantifying soluble fractions of brain lysates and thus could not account for differences 
in plaque composition. Nevertheless, insoluble Aβ fractions could be treated with formic 
acid and then analyzed for isoform differences. The Enzyme-linked immunosorbent 
assay (ELISA) could also be used in measurements due to the high resolution ability of 
the technique.  
  16 
S100 proteins may also influence plaque load at the level of molecular buildup or 
clearance. S100 interactions with the RAGE receptor may mediate transport of Aβ 
across the blood brain barrier. In the absence of S100A1 or B, it is possible that there is a 
shift in relative transport of Aβ in and out of systemic circulation and a consequent 





mice is not induced by changes in APP processing, 




















Alzheimer's Association (2011) Alzheimer's disease facts and figures. Alzheimers 
 Dement 7:208-244.  
 
Alzheimer's Association (2010) Early-onset Alzheimer's: I'm too young to have 
Alzheimer's disease. Pamphlet available at: http://www.alz.org/national/documen 
ts/brochure_earlyonset.pdf 
        
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403. 
 
Bradford, MM (1976) Rapid and sensitive method for the quantitation of microgram 
 quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 
 72: 248–254. 
 
Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP 
 processing enzymes and products. Neuromol Med 12:1-12. 
 
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya 
Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, 
Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing 
mutant presenilin 1. Nature 383:710-3. 
 
Holcomb LA, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Sright K, Saad I, 
 Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, 
 Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type 
 phenotype in transgenic mice carrying both mutant amyloid precursor protein 
 and presenilin 1 transgenes. Nat Med 4:97-100. 
 
Hoyaux D, Decaestecker C, Heizmann CW, Vogl T, Schafer BW, Salmon I, Kiss R and 
 Pochet R (2000) S100 proteins in Corpora amylacea from normal human brain. 
 Brain Res 867: 280-288.   
 
Hsiao, K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G 
 (1996) Correlative memory deficits, Ab elevation, and amyloid plaques in 
 transgenic mice. Science 274:99-102.  
 
Leclerc E, Sturchler E, Vetter SW (2010) The S100B/RAGE Axis in Alzheimer’s 
 disease. Cardiovasc Psychiatry Neurol 2010:539581 
 
  18 
Mori T, Koyama N, Arendash GW, Horikoshi Y, Tan J, Town T (2010) Overexpression 
 of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 
 mouse model of Alzheimer’s disease. Glia 58:300-314. 
 
Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, Shimoda T, Kamanaka Y, 
 Tateishi N, Asano T (2006) Arundic acid ameliorates cerebral amyloidosis and 
 gliosis in Alzheimer’s transgenic mice. J Pharmacol Exp Ther 318:517-578.  
 
Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B (2002) 
 Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 12:343-357 
Simón AM, Frechilla D, del Río J (2010) Perspectives on the amyloid cascade 
 hypothesis of Alzheimer's disease. Rev Neurol 50:667-75  
 
Supnet C, Bezprozvanny I (2010) The dysregulation of intracellular calcium in 
 Alzheimer disease. Cell Calcium 47:183–189. 
 
Tanzi R, Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: 
 A genetic perspective. Cell 120:545-555 
 
Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and 
 function. Biol Chem 283: 29615-29619. 
 
Turró-Garriga O, López-Pousa S, Vilalta-Franch J, Turon-Estrada A, Pericot-Nierga I, 
 Lozano-Gallego M, Hernández-Ferràndiz M, Soler-Cors O, Planas-Pujol X, 
 Monserrat-Vila S, Garre-Olmo J (2010) Annual economic cost of informal care 
 in Alzheimer’s disease. Rev Nerol 51:201-207. 
 
Zimmer DB, Chaplin J, Baldwin A, Rast M (2005) S100-mediated signal transduction in 








  19 
CONTACT INFORMATION 
 
Name: David Mathai 
Professional Address: c/o Dr. Danna Zimmer 
 Department of Veterinary Pathobiology 
 MS 4467 
 Texas A&M University 
 College Station, TX 77843 
Email Address: d.s.mathai@gmail.com 
Education: B.S., Biochemistry/Genetics  
 Texas A&M University, May 2013 
 Undergraduate Research Scholar 
 University Scholar 
 
